
Merck and Moderna report positive phase three results for personalized cancer vaccine
Merck and Moderna announced positive phase three trial results for an experimental mRNA cancer vaccine combined with Keytruda. The regimen significantly extended recurrence-free survival in over 1,100 high-risk melanoma patients, potentially marking a new treatment standard.















